Detalhe da pesquisa
1.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882206
2.
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
Nat Rev Cancer
; 7(7): 545-53, 2007 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-17585334
3.
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
Clin Cancer Res
; 30(6): 1093-1103, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37906083
4.
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.
JCO Precis Oncol
; 8: e2200667, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38237097
5.
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Proc Natl Acad Sci U S A
; 107(22): 10208-13, 2010 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20479250
6.
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Eur J Cancer
; 181: 92-101, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36641898
7.
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
Eur J Cancer
; 178: 23-33, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379186
8.
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Lancet Oncol
; 12(12): 1134-42, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21917518
9.
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
NPJ Breast Cancer
; 8(1): 98, 2022 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36038616
10.
HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
Curr Opin Oncol
; 23(6): 547-58, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21918439
11.
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
ESMO Open
; 5(5): e000743, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32893189
12.
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.
Eur J Cancer
; 137: 193-203, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32795875
13.
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
ESMO Open
; 5(6): e000979, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33154022
14.
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.
J Clin Oncol
; 38(34): 4120-4129, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052755
15.
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Clin Cancer Res
; 14(14): 4511-6, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18628466
16.
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.
PLoS One
; 14(4): e0216175, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31013327
17.
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
J Clin Oncol
; 37(7): 559-569, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30650045
18.
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
BMC Genomics
; 9: 239, 2008 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-18498629
19.
HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.
Clin Breast Cancer
; 8(1): 38-49, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18501058
20.
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
Clin Breast Cancer
; 8(3): 287-92, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18650162